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Introduction {#sec1}
============

Alzheimer disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia ([@bib62]). AD pathology begins decades before the onset of clinical symptoms and neuroinflammation is strongly indicated in its progression ([@bib54]). Neuroinflammation is mediated by microglia, the innate immune cells of the CNS. Microglia originate from erythromyeloid progenitor cells (EMPs) in the embryonic yolk sac ([@bib17]) and play pivotal roles in CNS development, as well as in tissue maintenance, injury response, and pathogen defense ([@bib9]). In AD, microglia are aberrantly activated and their normal functions are compromised ([@bib50]).

The major genetic risk factor for multifactorial late-onset AD (LOAD) ([@bib31]) is a gene variant apolipoprotein E4 (*APOE4*), whereas inherited genetic mutations in presenilin 1 (*PSEN1*), presenilin 2 (*PSEN2*), or amyloid precursor protein (*APP*) genes ([@bib53]) cause rarer early-onset familial AD (FAD) ([@bib2]). Human *APOE* is primarily expressed in three variants, the most abundant *APOE3* being neutral, and the rarest *APOE2* being protective in AD. All forms are involved in transport and elimination of lipids, but a common mode of action in the brain remains largely unexplored. *APOE* is highly expressed in microglia, and *APOE4* is shown to promote the neurodegeneration-associated inflammatory phenotype of mouse microglia ([@bib25]) and alter functions of human microglia-like cells (iMGLs) ([@bib30]). However, the precise role of *APOE4* in the development of AD remains elusive. *PSEN1* and *APP* participate in the production of neurotoxic amyloid-beta (Aβ) peptide, the main component of the amyloid plaques found in the brains of AD patients. The expression of *APP* and *PSEN1* in microglia is shown to increase upon brain insults ([@bib4], [@bib38]) and these genes are implicated in inflammatory processes ([@bib32], [@bib65]), but it is unclear whether they contribute to AD through microglial functions.

Given the central role of microglia in AD and the lack of knowledge of FAD mutations or *APOE4* in human microglia, we established a method to generate iMGLs from induced pluripotent stem cells (iPSCs) carrying *APOE4* genotype or *PSEN1ΔE9* or *APPswe* mutations. iMGLs have a robust microglial phenotype and resemble recently published iPSC-derived microglia ([@bib1], [@bib13], [@bib34]). We conclude that *APOE4* genotype has a substantial impact on the function of iMGLs, whereas the FAD mutations have only minor effects. *APOE4* contributes particularly to reduced migration, increased proinflammatory responses and defective glycolytic and mitochondrial metabolism. This study elucidates the role of human microglia in disease pathogenesis in FAD and LOAD.

Results {#sec2}
=======

iPSCs Differentiate into iMGLs through Primitive Hematopoiesis {#sec2.1}
--------------------------------------------------------------

We developed a high-yield 24-day protocol to differentiate human iPSCs into iMGLs. To recapitulate microglial ontogeny from the yolk sac ([@bib16], [@bib23], [@bib52], [@bib59]), we used small molecules under defined oxygen conditions to direct differentiation through primitive EMPs followed by microglial maturation ([Figure 1](#fig1){ref-type="fig"}A). Morphological changes and the expression of the key markers for each stage of differentiation were assessed by flow cytometry and phase-contrast microscopy ([Figures 1](#fig1){ref-type="fig"}B--1E and [S1](#mmc1){ref-type="supplementary-material"}).Figure 1iPSCs Differentiate into iMGLs through Primitive Hematopoiesis(A--E) Schematic protocol (A). Percentages of positive cells analyzed by flow cytometry for markers of (B) pluripotency, (C) EMPs and mesodermal brachyury (BRAC), (D) primitive EMPs, and (E) and mature microglia. n = 4 cell lines, repeated in 3 batches.(F) The expression of microglial signature genes in RNA sequencing (RNA-seq) data of D24 iMGLs as log2 CPM values. n = 3 batches, 4 cell lines.(G) Hierarchical clustering of RNA-seq data shows that our iMGLs cluster with published iMGLs and human microglia (MG), but are distinct from dendritic cells (DCs), monocytes (CD14M and CD16M), iPSCs, and hematopoietic progenitor cells (HPCs) ([@bib1]).(H--J) Immunostainings of D24 iMGLs (H). Repeated with two batches for all cell lines. Images of iMGLs labeled with IBA1 (red) in (I) 3D-Matrigel co-culture with neurons and in (J) cerebral brain organoids. Repeated with two batches for 2--4 cell lines. Scale bars as μm. Data presented mean ± SEM.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

During the first differentiation days (D0--2), mesodermal lineage was induced with BMP4, Activin A and CHIR99021 under low oxygen (5% O~2~) conditions and was accompanied with a reduction of pluripotency markers ([Figure 1](#fig1){ref-type="fig"}B). When the expression of mesodermal brachyury was the highest, 48 h after initiation ([Figure 1](#fig1){ref-type="fig"}C), basic fibroblast growth factor (bFGF), SB431542, vascular endothelial growth factor (VEGF), and insulin were applied to evoke hemogenic differentiation. Subsequently, the areas of endothelial-like cells formed ([Figure S1](#mmc1){ref-type="supplementary-material"}) and the expression of hemogenic EMP markers KDR, CD117 (c-kit), VE-cadherin, and CD34 increased ([Figure 1](#fig1){ref-type="fig"}C). On D6--7, loosely attached round cells appeared with a high expression of primitive EMP markers CD235a ([@bib56]) and CD41a ([@bib22]) ([Figure 1](#fig1){ref-type="fig"}D). MCSF1 and interleukin-34 (IL-34) were used to induce microglial differentiation and expansion on ultra-low attachment (ULA) dishes. On maturation, the expression of myeloid markers increased and on D24, 88% of cells expressed CD11b, 99% CD45, and 91% IBA1 when cultured on ULA dishes ([Figure 1](#fig1){ref-type="fig"}E). To mature iMGLs for functional experiments, D16 progenitors were cultured on poly-D-lysine (PDL)-coated vessels until D24 to promote ramified and elongated morphology and IBA1 expression ([Figure S1](#mmc1){ref-type="supplementary-material"}).

The microglial identity of iMGLs was confirmed with whole-transcriptome analysis and qRT-PCR ([Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc2){ref-type="supplementary-material"}). The microglial signature genes, *C1QA*, *GAS6*, *GPR34*, *MERTK*, *PROS1*, and *TMEM119* ([@bib7]), were highly expressed (logCPM\>2, [Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}). Comparison of RNA sequencing profiles to published dataset [GSE89189](ncbi-geo:GSE89189){#intref0010} ([@bib1]) using microglia genes ([@bib28]) revealed that iMGLs cluster with published iPSC-derived microglia ([@bib1]), as well as with human microglia ([@bib64]), but remain distinct from iPSCs and other tissue myeloid cells ([Figures 1](#fig1){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}). Immunostaining of D24 iMGLs verified ubiquitous expression of IBA1, CX3CR1, and PU.1 ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}) and, importantly, microglia-specific proteins TMEM119, P2RY12, and TREM2 ([@bib6]) ([Figure 1](#fig1){ref-type="fig"}H). Furthermore, iMGLs spontaneously migrated into 3D co-cultures and adopted a ramified morphology ([Figures 1](#fig1){ref-type="fig"}I and 1J). Thus, the iMGLs generated through induction of primitive EMPs show a typical microglia-like genetic signature and protein expression.

iMGLs Express *APP* and *PSEN1*, and *PSEN1*ΔE9 Mutation Leads to Expected Alterations in PSEN1 Endoproteolysis {#sec2.2}
---------------------------------------------------------------------------------------------------------------

To assess the reproducibility of the differentiation protocol, we successfully generated iMGLs from 16 different iPSC lines ([Table S3](#mmc1){ref-type="supplementary-material"}) with a 20-fold average yield. iPSCs originated from adult donors. Neutral *APOEɛ3/3* alleles (*APOE3*) were carried by five healthy subjects, two subjects with familial *KM670/*671NL Swedish double mutation in *APP* (*APPswe*) ([@bib36]), and two with a familial 4.6-kb deletion of exon 9 in *PSEN1* (*PSEN1*ΔE9) ([@bib11]). Three subjects carried *APOEɛ4/4* alleles (*APOE4*) ([@bib3], [@bib14], [@bib37], [@bib44]). One *APPswe* carrier had symptomatic AD (referred spAPP) and one was presymptomatic (pAPP) with no clinical diagnosis. Similarly, one *PSEN1ΔE9* carrier was presymptomatic (pPSEN) and one had AD diagnosis (spPSEN). The effect of *PSEN1ΔE9* mutation was validated with gene-corrected isogenic control lines from the symptomatic (spISO) and the presymptomatic (pISO) *PSEN1*ΔE9 carriers ([@bib42]). Pluripotency and the karyotype of previously unpublished pAPP, *APOE3*, and *APOE4* lines were characterized ([Figure S3](#mmc1){ref-type="supplementary-material"}).

We next analyzed the effect of genetic background on processing of APP protein into toxic Aβ. *APPswe* iMGLs showed 2.5-fold increase in PSEN1 protein but no consistent changes in APP compared with control cells ([Figures 2](#fig2){ref-type="fig"}A--2D). As expected, *PSEN1*ΔE9 iMGLs showed a robust accumulation of PSEN1 and a 3-fold increase in APP compared with isogenic controls ([Figures 2](#fig2){ref-type="fig"}E--2H), thereby establishing that the *PSEN1*ΔE9 mutation resulted in a loss of γ-secretase cleavage of APP. Furthermore, *APOE3* and *APOE4* lines showed low levels of APP, PSEN1, and C-terminal fragments of PSEN1, and no differences between the genotypes ([Figures 2](#fig2){ref-type="fig"}I--2L). Quantification of Aβ fragments from cell lysates and culture media revealed that iMGLs had no intracellular Aβ and secreted only Aβ1-42 at similar levels regardless of the genotype ([Figure 2](#fig2){ref-type="fig"}M). Taken together, all cell lines had a normal karyotype and expressed FAD mutations or LOAD risk variants supporting their use for studying AD, even though genotypes failed to alter iMGL Aβ production.Figure 2iMGLs Express APP and PSEN1 Proteins, and *PSEN1*ΔE9 Mutation Leads to Expected Alterations in PSEN1 Endoproteolysis(A--L) Western blots for full-length (FL) and C-terminal fragment (CTF) of PSEN1 and APP proteins from 3 batches of control (CTRL) and *APPswe* (pAPP, spAPP) iMGLs (A). GAPDH and b-ACTIN as loading controls. Quantification of blots normalized to GAPDH for (B) PSEN1-FL, (C) PSEN1-CTF, and (D) APP protein. n = 3 batches. Respective western blots (E) and quantification (F--H) for *PSEN1ΔE9* iMGLs (pPSEN, spPSEN) and their isogenic controls (pISO and spISO). n = 2--5 batches. Western blots (I) for *APOE3* and *APOE4* iMGLs and quantification (J--L) for the proteins. n = 3 batches.(M) Aβ 1-42 levels in cell culture medium after 48 h analyzed by ELISA. n = 2--5 batches for *APP* and *PSEN*; n = 3 wells for *APOE* repeated in three batches.Data presented mean ± SEM unpaired two-tailed t test,^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. p, presymptomatic; sp, symptomatic. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

ATP and ADP Evoke Intracellular Calcium Transients in iMGLs {#sec2.3}
-----------------------------------------------------------

Since calcium may control microglial functions under resting and activated conditions ([@bib19]), we next investigated intracellular calcium \[Ca^2+^\]~i~ transients in response to ATP and ADP. The representative traces of \[Ca^2+^\]~i~ transients demonstrate similar responses in all genotypes ([Figure 3](#fig3){ref-type="fig"}A). The average amplitudes of the responding cells were equal in control and *APPswe* iMGLs ([Figure 3](#fig3){ref-type="fig"}B). In contrast, there was a 22% reduction in ATP-responsive cells in pAPP iMGLs and a 27% reduction in ADP-responsive cells in both pre- and symptomatic *APPswe* iMGLs compared with control ([Figure 3](#fig3){ref-type="fig"}C). Equal amplitudes and percentages of responsive cells were observed for isogenic and *PSEN1*ΔE9 iMGLs ([Figures 3](#fig3){ref-type="fig"}D and 3E), and for *APOE3* and *APOE4* iMGLs ([Figures 3](#fig3){ref-type="fig"}F and 3G) demonstrating the consistent functionality of iMGLs harboring these genotypes. Collectively, all cell lines responded to ADP and ATP by intracellular calcium release, supporting microglia-like functionality of the iMGLs. Reduction in *APPswe* responses suggests that FAD mutation can alter intracellular calcium signaling.Figure 3ATP and ADP Evoke Intracellular Calcium \[Ca^2+^\]~i~ Transients in iMGLs(A) Example traces of \[Ca^2+^\]~i~ transients following 100 μM ATP (left panel) and ADP (right panel) applications for 5 s (indicated by bars) in iMGLs loaded with the Ca^2+^ indicator Fluo-4 AM.(B) The ratio of maximum amplitudes normalized to amplitudes evoked by ionomycin that was applied in the end of experiment and used as inclusion criteria. n = 4 batches, each with 9--10 coverslips, altogether 3,994 CTRL, 3,015 pAPP, and 3,906 spAPP cells.(C--E) Percentages of ATP- and ADP-responsive cells in *APPswe* lines compared with control iMGLs (C). Ratio of maximum amplitudes (D) and percentages of responsive cells (E) obtained from isogenic and *PSENΔE9* iMGLs. n = 4 batches, each with 9--12 coverslips, altogether 1,969 pISO, 2,355 spISO, 1,856 pPSEN, and 2,823 spPSEN cells.(F and G) Similar data for *APOE3* and *APOE4* iMGLs. n = 4 coverslips, altogether 482 *APOE3* and 991 *APOE4* cells, repeated in three batches.Data presented mean ± SEM unpaired two-tailed t test or one-way ANOVA followed by Bonferroni\'s post hoc test, ^∗^p \< 0.05, ^∗∗^p \< 0.01. CTRL, control; p, presymptomatic; sp, symptomatic; PSEN, *PSEN1ΔE9*; APP, *APPswe*; and ISO, isogenic control iMGLs.

Chemokinesis Is Accelerated in *APPswe* and *PSEN1ΔE9* iMGLs but Decelerated in *APOE4* iMGLs {#sec2.4}
---------------------------------------------------------------------------------------------

Microglial migration to the injury site is crucial for maintaining homeostasis in the brain. We analyzed the chemokinesis of iMGLs using a scratch wound assay with live-cell imaging for 24 h ([Figure 4](#fig4){ref-type="fig"}A). Acute application of ATP and ADP, which can be released from injured neurons, increased migration in all tested cell lines, whereas soluble oligomeric Aβ (sAβ) failed to alter migration ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}). We observed increased basal migration in *APPswe* lines compared with control iMGLs as well as in spPSEN iMGLs compared with their isogenic controls ([Figures 4](#fig4){ref-type="fig"}D, 4F, and [S4](#mmc1){ref-type="supplementary-material"}). In contrast, *APOE4* genotype reduced basal migration ([Figures 4](#fig4){ref-type="fig"}E and 4F). ATP or ADP induced similar increase in migration in all genotypes ([Figure 4](#fig4){ref-type="fig"}G). In contrast, migration evoked by fractalkine was restrained in *APOE4* iMGLs compared with *APOE3* ([Figures 4](#fig4){ref-type="fig"}H and 4I), indicating impairment in motility in response to this neuron-derived chemokine. The migration was reduced if fetal bovine serum (FBS) was withdrawn from cell culture and therefore the experiments were performed in the presence of FBS ([Figure 4](#fig4){ref-type="fig"}S). Overall, all iMGL lines migrated and responded to different stimuli as expected for microglia. A reduction in *APOE4* and a mild increase in APP and PSEN1 iMGLs suggest that LOAD risk variant and FAD mutations have different effects on microglial functions.Figure 4Chemokinesis Is Accelerated in *APPswe* and *PSEN1ΔE9* iMGLs but Decelerated in *APOE4* iMGLs(A) Representative images of iMGLs in scratch wound migration assay at 0, 12, and 24 h time points. Scale bar 300 µm.(B) Wound densities measured for 25 h with vehicle (VEH), 100 μM ATP, 100 μM ADP, or 1-μM soluble sAβ treatments.(C--E) Wound densities at 24 h normalized to vehicle (C). Time curves for (D) control (CTRL) and *APPswe* (APP), and (E) *APOE3* and *APOE4* iMGLs.(F) Wound densities at 24 h normalized to control or isogenic (ISO) iMGLs.(G) A heatmap for increase (darker color) or decrease (lighter color) in wound density compared with vehicle. White asterisks indicate significance compared with vehicle and black asterisks to control genotype.(H) Time curves for wound density with 100 μM fractalkine (CX3CL1) treatment in *APO3* iMGLs.(I) Corresponding wound density at 24 h normalized to vehicle for *APOE* iMGLs. Curve graphs show a representative experiment of three replicates, n = 3--5 wells. Boxplots and heatmap show normalized results from n = 3--5 replicate batches.Data presented mean ± SEM, unpaired two-tailed t test, ^∗^p \< 0.05, ^∗^p \< 0.01, ^∗∗∗^p \< 0.001. p, presymptomatic; sp, symptomatic. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Phagocytosis Is Dampened in *APOE4* iMGLs, but Not in *APPswe* or *PSEN1ΔE9* iMGLs {#sec2.5}
----------------------------------------------------------------------------------

Since microglia fail to efficiently clear Aβ plaques in AD ([@bib29]), we examined phagocytosis by live-cell imaging. iMGLs spontaneously phagocytosed pHrodo Zymosan A bioparticles ([Figures 5](#fig5){ref-type="fig"}A and 5B) equivalently despite of their genotypes ([Figures 5](#fig5){ref-type="fig"}C, 5D, and [S4](#mmc1){ref-type="supplementary-material"}). Since *APOE4* variant was recently reported to reduce phagocytosis in iPSC-derived microglia ([@bib30]), we investigated *APOE* iMGLs also with confocal microscopy and with fewer number of larger fluorescein isothiocyanate (FITC) Zymosan A bioparticles to count internalized particles ([Figures 5](#fig5){ref-type="fig"}E and 5F). Indeed, despite the equal overall intensity of phagocytosed pHrodo particles ([Figure 5](#fig5){ref-type="fig"}G), *APOE4* iMGLs ingested a smaller number of FITC particles per cell compared with *APOE3* ([Figure 5](#fig5){ref-type="fig"}H).Figure 5Phagocytosis Is Dampened in *APOE4* iMGLs, but not in *APPswe* or *PSEN1ΔE9* iMGLs(A and B) Representative images of phagocytosed green pHrodo Zymosan A bioparticles in iMGLs at 5 h.(C) Time curves for pHrodo fluorescence intensity in control (CTRL) and *APPswe* (APP) iMGLs normalized to cell amount.(D) Respective boxplots at 5 h normalized to control or isogenic (ISO) iMGLs.(E and F) Representative images of phagocytosed FITC Zymosan A bioparticles in iMGLs.(G) pHrodo time curves for *APOE3* and *APOE4* iMGLs.(H) Percentages of *APOE* iMGLs that internalized certain number of FITC particles per cell. n = 290--750 cells.(I--L) pHrodo intensity at 5 h, after 24 h pretreatment with 100 ng/mL LPS, 20 ng/mL IFN-γ, or LPS-IFN-γ, or with simultaneous treatment with 0.5 μM soluble sAβ or fibrillar fAβ, compared with vehicle (Veh) in APPswe (I), pPSEN (J), spPSEN (K), and APOE (L) iMGLs.(M) Representative image of phagocytosed green fluor-Aβ1-42 in iMGLs at 5 h.(N) Time curves for fluorescence intensity of fluor-Aβ in control and *APPswe* iMGLs.(O) Respective bar graphs at 5 h normalized to control iMGLs.(P) Representative image of iMGLs treated with fluor-Aβ and fAβ depicting enlarged vacuoles. Scale bars, 50 μm. Curve graphs show a representative experiment of 3 replicates, n = 4 wells. Boxplots and bar graphs show normalized results from n = 2--6 replicate batches.Data presented mean ± SEM unpaired two-tailed t test or two-way ANOVA with Bonferroni\'s post hoc test,^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. p, presymptomatic; sp, symptomatic; PSEN, *PSEN1ΔE9* iMGLs. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Next, we tested whether proinflammatory stimuli attenuate the phagocytosis of iMGLs as reported for murine microglia ([@bib24]). iMGLs were pretreated with lipopolysaccharide (LPS), interferon γ (IFN-γ), or both LPS and IFN-γ (LPS-IFN-γ) for 24 h or treated with sAβ or insoluble fibrillary (fAβ) Aβ1-42 at the time of particle application. Unexpectedly, LPS failed to alter phagocytosis of pHrodo beads, whereas IFN-γ or LPS-IFN-γ suppressed it ([Figures 5](#fig5){ref-type="fig"}I--5L). Withdrawal of stimuli before to the measurement did not restore IFN-γ-mediated suppression, but in the LPS-pretreated group phagocytosis was first abrogated and then potentiated 5 h after withdrawal ([Figure S4](#mmc1){ref-type="supplementary-material"}). Addition of fAβ only slightly enhanced the phagocytosis of pHrodo beads in presymptomatic isogenic and *PSEN1ΔE9* iMGLs, whereas sAβ had no effect ([Figures 5](#fig5){ref-type="fig"}J and 5K).

iMGLs phagocytosed also fluorescent Aβ1-42 spontaneously ([Figure 5](#fig5){ref-type="fig"}M). *APPswe* iMGLs internalized 1.2-fold more Aβ compared with their controls ([Figures 5](#fig5){ref-type="fig"}N and 5O). *PSEN1ΔE9* or *APOE4* genotypes had no effect ([Figure S4](#mmc1){ref-type="supplementary-material"}). To test the impact of proinflammatory activation on Aβ phagocytosis, we treated the cells with LPS, sAβ, or fAβ simultaneously with fluorescent Aβ. LPS reduced Aβ phagocytosis only in isogenic and *PSEN1ΔE9* iMGLs ([Figure S4](#mmc1){ref-type="supplementary-material"}), and fAβ induced engorged vacuoles in all genotypes ([Figure 5](#fig5){ref-type="fig"}P). In summary, iMGLs presented microglia-like phagocytosis of both particles and Aβ and altered phagocytosis upon inflammatory stimuli. Only *APOE4* iMGLs showed mild impairment in phagocytosis.

Cytokine Release under Proinflammatory Conditions Is Aggravated in *APOE4* iMGLs but Decreased in *PSEN1*ΔE9 and *APPswe* iMGLs {#sec2.6}
-------------------------------------------------------------------------------------------------------------------------------

To study cytokine release, conditioned medium was analyzed with cytokine bead array after 24 h treatment with vehicle, LPS, IFN-γ, or LPS-IFN-γ ([Figure 6](#fig6){ref-type="fig"}A). Under basal conditions, the levels of proinflammatory cytokines IL-6, tumor necrosis factor alpha (TNF-α), regulated on activation, normal T cell expressed and secreted (RANTES), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were negligible (\<1 pg/mL), whereas IL-8 levels were small (10 pg/mL) and MCP1 reached even 1 ng/mL concentrations ([Figure 6](#fig6){ref-type="fig"}A). As expected, iMGLs robustly responded to LPS with significant induction in all measured cytokines. The combination of LPS-IFN-γ triggered similar or even higher release of cytokines except GM-CSF, whereas IFN-γ alone induced only small, yet detectable, increase.Figure 6Cytokine Release under Proinflammatory Conditions Is Aggravated in *APOE4* iMGLs but Decreased in *PSEN1ΔE9* and *APPswe* iMGLs(A) iMGLs secrete cytokines when stimulated for 24 h with LPS 100 ng/mL, IFN-γ 20 ng/mL, or their combination LPS-IFN-γ as measured from media by cytometric bead array assay. Representative graphs. n = 4 wells.(B) spAPP iMGLs released less TNF-α, and pAPP less TNF-α and MCP1, compared with control iMGLs in response to LPS-IFN-γ treatment.(C) *PSEN1*ΔE9 iMGLs released less IL-6, TNF-α, and RANTES compared with isogenic iMGLs.(D) In contrast, *APOE4* iMGLs released aggregated amounts of TNF-α and IL-8 compared with *APOE3*. For (B--D) n = 3--6 batches, each with 4 wells.Data presented mean ± SEM unpaired two-tailed t test, ^∗^p \< 0.05, ^∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}. CTRL, control; p, presymptomatic; sp, symptomatic; PSEN, *PSEN1ΔE9*; APP, *APPswe*; and ISO, isogenic control iMGLs.

We investigated further LPS-IFN-γ effect since it simulates *in vivo* damage-associated molecular patterns acting on Toll-like receptors and IFN-γ produced by CNS cells ([@bib47]). *APPswe* iMGLs produced less TNF-α and MCP1 in response to LPS-IFN-γ compared with control iMGLs ([Figure 6](#fig6){ref-type="fig"}B). Similarly, *PSEN1ΔE9* iMGLs secreted less IL-6, TNF-α, and RANTES compared with their isogenic controls ([Figure 6](#fig6){ref-type="fig"}C). Concomitantly, LPS or IFN-γ alone resulted in decreased cytokine secretion in iMGLs harboring these genotypes ([Figure S4](#mmc1){ref-type="supplementary-material"}). In contrast, *APOE4* iMGLs produced more cytokines compared with *APOE3* iMGLs upon treatment with LPS-IFN-γ ([Figure 6](#fig6){ref-type="fig"}D), LPS or IFN-γ ([Figure S4](#mmc1){ref-type="supplementary-material"}). Taken together, *APOE4* genotype increased cytokine secretion, whereas FAD mutations reduced it.

Metabolism of iMGLs Is Altered under Pro- and Anti-inflammatory Stimuli and by *APOE4* Genetic Background {#sec2.7}
---------------------------------------------------------------------------------------------------------

To investigate metabolism under anti- or proinflammatory stimuli we measured the cellular respiration of iMGLs after 24 h treatment with IL-4, LPS, IFN-γ, or LPS-IFN-γ ([Figures 7](#fig7){ref-type="fig"}A and 7B). An anti-inflammatory IL-4 increased parameters of oxidative respiration, whereas proinflammatory LPS and LPS-IFN-γ reduced them ([Figure 7](#fig7){ref-type="fig"}C). IFN-γ increased all parameters except ATP production ([Figure 7](#fig7){ref-type="fig"}C). Compared with LPS, LPS-IFN-γ reversed oxidative parameters toward the levels of the vehicle ([Figure 7](#fig7){ref-type="fig"}C). On the contrary, all proinflammatory stimuli increased anaerobic glycolysis and glycolytic capacity indicating a shift from oxidative respiration toward anaerobic glycolysis ([Figure 7](#fig7){ref-type="fig"}D). The pooled data for LPS normalized to the vehicle confirmed the equal shifts in all genotypes, except the proton leak was increased in pAPP and glycolytic capacity in spAPP compared with control iMGLs ([Figure 7](#fig7){ref-type="fig"}E).Figure 7Metabolism of iMGLs Is Altered under Pro- and Anti-inflammatory Stimuli and by *APOE4* Genetic Background(A) Representative oxygen consumption rate (OCR) curves for iMGLs following 24 h vehicle (VEH), LPS, IL-4, IFN-γ, and LPS-IFN-γ treatments, all 20 ng/mL. n = 3--5 wells.(B--D) Corresponding extracellular acidification rate (ECAR) curves (B). Mitochondrial parameters calculated from (C) OCRs in (A and D) from ECARs in (B).(E--H) Heatmap indicating decrease (blue) or increase (red) in fold change of mitochondrial parameters of LPS-treated iMGLs compared with vehicle (E). White equals 1. n = 5 CTRL, n = 4 pAPP, n = 2 spAPP, n = 3 *APOE3*, and n = 2 *APOE4* batches with 10 wells; n = 1 isogenic, and n = 3 *PSEN1* batches with 4--5 wells. Representative OCR and ECAR curves for (F) control and *APPswe*, (G) isogenic and *PSEN1*ΔE9, and for (H) *APOE4* and *APOE3* iMGLs. n = 5--10 wells, repeated with three batches.(I) Mitochondrial parameters calculated from OCRs and ECARs in (H) ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 compared with vehicle, \#compared with LPS, †compared with IFN-γ, two-tailed unpaired t test. Olig, oligomycin; FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; R/A, rotenone and antimycin A, each 1 μM. CTRL, control; p, presymptomatic; sp, symptomatic; PSEN, *PSEN1ΔE9*; APP, *APPswe*; and ISO, isogenic control iMGLs.

To elucidate whether AD-predisposing genetic backgrounds provoked a metabolic shift toward a proinflammatory glycolytic phenotype, we next compared respiration between the genotypes without stimulus. FAD mutations did not alter the metabolism ([Figures 7](#fig7){ref-type="fig"}F and 7G). In contrast, oxygen consumption rate was lower in *APOE4* iMGLs compared with *APOE3* iMGLs, demonstrating a similar shift as with LPS treatment ([Figure 7](#fig7){ref-type="fig"}H). Surprisingly, the *APOE4* genotype led to a reduced extracellular acidification ([Figure 7](#fig7){ref-type="fig"}H), whereas LPS had increased it ([Figure 7](#fig7){ref-type="fig"}A). In accordance, *APOE4* iMGLs showed a reduction in all mitochondrial parameters compared with the *APOE3* iMGLs ([Figure 7](#fig7){ref-type="fig"}I).

Discussion {#sec3}
==========

Here, we demonstrate the power of iPSC-derived microglia to elucidate distinct functional phenotypes of human microglia in disease. Differentiated iMGLs show a typical microglia-like gene and protein expression and respond to inflammatory stimuli robustly in multiple functional assays. We pinpoint specific phenotypes in iMGLs with three AD-predisposing genetic backgrounds, revealing that *APOE4* has a profound impact on several aspects of microglial functionality, whereas *APPswe* and *PSEN1ΔE9* have minor effects. The distinct phenotypes were observed without changes in amounts of Aβ, suggesting that Aβ burden associated with *PSEN1ΔE9*, *APPswe*, and *APOE4* is of neuronal and astrocytic origin ([@bib39], [@bib51]), and that human microglia with these genotypes harbor alternative mechanisms underlying development and progression of AD.

This study reveals that *APOE4* iMGLs are fundamentally unable to mount normal microglial functionality as hypothesized for AD ([@bib50]). The *APOE4* genotype impaired phagocytosis and migration, and aggravated inflammatory responses of iMGLs, suggesting that *APOE4* confers iMGLs toward a proinflammatory disease-associated microglial (DAM) phenotype ([@bib30], [@bib43]). We also reported similar responses to proinflammatory IFN-γ and LPS in phagocytosis and cytokine release, consistent with murine microglia ([@bib58], [@bib24]). *APOE4* conferred decrease in migration at basal level and in response to fractalkine, although no changes in P2RY12 or CX3CR1 expression were observed. Furthermore, no increase in chemokinesis upon Aβ exposure was seen in scratch wound assay, although invasion assays could be more relevant to study chemotaxis. In mouse models, the switch to DAM is triggered by TREM2-APOE interaction ([@bib25]); however, exact mechanisms underlying human *APOE4*-induced inflammatory phenotype in AD microglia remain incompletely defined.

We extend these findings to highlight a novel role of *APOE4* in impaired metabolism of microglia. The cellular metabolism was robustly shifted in all iMGLs in response to inflammatory stimuli. LPS induced switch from oxidative metabolism to anaerobic glycolysis in line with recent evidence ([@bib15], [@bib45]), whereas less studied IFN-γ increased both oxidative and glycolytic metabolism, supporting its role in the priming of microglia to meet the energy demands upon activation ([@bib57]). Metabolic shift toward glycolysis is reported to occur also in AD microglia with *TREM2* mutations ([@bib60]). On the contrary, we observed a general downregulation of all metabolic parameters, both oxidative and glycolytic, in *APOE4* iMGLs. Thus, *APOE4*-induced inhibition of microglial metabolism and phagocytosis accompanied with heightened cytokine release may partly explain the development AD-related plaque burden in the brain.

In contrast to *APOE4*, the FAD mutations caused only a slight decrease in proinflammatory cytokine release and increase in chemokinesis. Unlike that recently reported for sporadic AD lines ([@bib63]), *APPswe* and *PSEN1*ΔE9 mutations did not predispose iMGLs toward a more proinflammatory phenotype, but rather toward a senescent phenotype incapable of implementing a full inflammatory response. Cytokine-mediated inflammation has been strongly established in multiple animal models of AD, but human patients show varied results ([@bib61], [@bib55], [@bib5]). *PSEN*2 rather than *PSEN1* has been reported to modulate microglial cytokine release ([@bib21]). iMGLs secreted similar levels of cytokines with human autopsy microglia ([@bib49]), and decrease in FAD iMGLs is consistent with lower cytokine levels reported in certain brain areas of AD patients compared with non-AD subjects ([@bib27]). These mild and opposite outcomes in iMGLs with FAD mutations compared with the *APOE4* genotype indicate that functionality of human microglia with different genetic backgrounds is sensitively and distinctly modulated, and that pathogenic effects of *APPswe* and *PSEN1ΔE9* are mainly mediated by other cell types.

To elucidate the aforementioned functional AD phenotypes of human microglia we used a novel method to generate iMGLs. Several groups have recently reported protocols ([@bib13], [@bib18], [@bib35], [@bib46]) to produce microglia from stem cells, and our protocol closely resembles methods from the Blurton-Jones group ([@bib1], [@bib34]). In our method, differentiation is initiated simply with a defined number of single cells to generate functional high-purity microglia-like cells in 24 days with a 20-fold yield. Importantly, we confirmed that most cells differentiate through primitive EMPs, the most critical step making microglia distinct from other tissue macrophages ([@bib22], [@bib56]). In our hands, low oxygen conditions during the early stages were pivotal in yielding considerable numbers of primitive EMPs, even though a recent study ([@bib34]) suggests that normoxic conditions would be advantageous for simplifying equipment. The microglia-like identity of iMGLs was confirmed with high expression of microglial signature genes and low expression of macrophage genes, since microglial genes are expressed to some extent also in primitive macrophages ([@bib18]).

Considering that iPSC-models fundamentally produce rather immature cell types, the iMGLs probably represent relatively young microglia. In accordance, P2RY12, a marker for mature microglia, was expressed at a relatively low level ([@bib6], [@bib7]). iMGLs also exhibited a high migration capacity in response to chemotactic signals, such as ATP ([@bib12], [@bib26]), as has been shown previously for young microglia ([@bib8]). Thus, we recognize that the method can be further optimized by utilizing the advantages presented in other iPSC-derived microglia protocols. FBS could be replaced with more defined supplements to reduce potential unwanted priming that might mask subtle genotype differences and additional maturation factors, such as transforming growth factor β, CD200, and CX3CL1, could be applied.

Taken together, we report here a short and relatively easy to use protocol to differentiate iMGLs from iPSCs. We characterize the effect of AD-predisposing genetic backgrounds on the functionality of cells featuring a profound impact of *APOE* on the phenotype of microglia. The current study highlights the importance of investigating the role of gene variants in human microglia and provides a useful, clinically relevant model for studying microglia in disease.

Experimental Procedures {#sec4}
=======================

See further details in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Generation and Maintenance of iPSCs {#sec4.1}
-----------------------------------

iPSC lines Ctrl1, Ctrl3, and PSEN1, and their isogenic control lines were previously generated and characterized ([@bib42]) by the approval of the committee on Research Ethics of Northern Savo Hospital district (123/2016) after written consent from the subjects. pAPP and spAPP lines were approved by the ethical review board of Karolinska Institutet/University (2017/834--31/1), and spAPP was characterized previously ([@bib41]). HC1-3 and LOAD1-3 lines were characterized ([@bib3], [@bib37], [@bib44]) with the approval of the University of Wollongong human research ethics committee (HE13/299). Previously uncharacterized lines pAPP, TOB0002c3, and MBE2968c1 were approved by the ethical review board of Karolinska Institutet/University (2017/834--31/1), or by the human research ethics committees of the Royal Victorian Eye and Ear Hospital (11/1031H, 13/1151H-004), University of Melbourne (1545394), University of Tasmania (H0014124), with the requirements of the National Health & Medical Research Council of Australia and conformed with the Declarations of Helsinki ([@bib33]). Fibroblasts were isolated and cultured as described previously ([@bib10], [@bib48]) and were reprogrammed to iPSCs either with Sendai virus using CytoTune 1.0 kit (Invitrogen) ([@bib20]) or by nucleofection (Lonza Amaxa Nucleofector) ([@bib40]). iPSCs were maintained in Essential 8 Medium (E8, Gibco) on Matrigel (Corning) and were passaged with 0.5 mM EDTA (Invitrogen) in the presence of 5 μM Y-27632 (Selleckchem). All iPSCs were confirmed to be sterile and all cell cultures were tested for mycoplasma using a MycoAlert Kit (Lonza).

Differentiation of iMGLs {#sec4.2}
------------------------

On D0, iPSCs were dissociated to single cells with 0.5 mM EDTA or Accutase (Innovative Cell Technologies) and were replated at a density of 6,000--16,000 cells/cm^2^ on Matrigel in E8, 0.5% penicillin/streptomycin (P/S) (50 IU/50 mg/mL), 5 ng/mL BMP4, 25 ng/mL Activin A (both from PeproTech or Miltenyi Biotec), 1 μM CHIR 99021 (Axon or Stem Cell Technologies) and 10 μM Y-27632. The cells were maintained in low oxygen at 5% O~2~, 5% CO~2~, 37°C. On D1, the medium was replaced with a lower concentration of 1 μM Y-27632. After 48 h on D2 the medium was changed to differentiation base medium (dif-base) containing DMEM/F-12, 0.5% P/S, 1% GlutaMAX, 0.0543% sodium bicarbonate (all from Thermo Fisher Scientific), 64 mg/L L-ascorbic acid and 14 μg/L sodium selenite (both from Sigma). The dif-base was supplemented with 100 ng/mL FGF2, 50 ng/mL VEGF (both from PeproTech), 10 μM SB431542 (Selleckchem or Stem Cell Technologies), and 5 μg/mL insulin (Sigma). On D4, the media was replaced by dif-base supplemented with 5 μg/mL insulin, 50 ng/mL FGF2, VEGF, IL-6, and thyroid peroxidase, and 10 ng/mL IL-3 and stem cell factor. From then on, the cells were maintained in a normoxic incubator. Fresh EMP medium was changed daily until D8, when floating round EMPs were collected from the top of the monolayer. After centrifugation 300 × *g* for 5 min, 350,000 cells/mL were transferred to ULA dishes (Corning) in microglial medium containing Iscove\'s modified Dulbecco\'s medium (Thermo Fisher Scientific), 0.5% P/S, and 10% heat inactivated FBS (Biowest) or DMEM/F12, 0.5% N~2~, 0.5% B27 supplemented with 5 μg/mL insulin, 5 ng/mL MCSF, and 100 ng/mL IL-34 (both from PeproTech). On D10, the cell suspension was changed by centrifuging and 350,000 cells/mL were seeded back to ULA dishes in microglial maturation medium supplemented with 10 ng/mL MCSF and 10 ng/mL IL-34. This medium was changed similarly every second day until D16, when the cells were detached from ULA dishes with Accutase and replated on PDL-coated (Sigma) nunclon cell culture-treated plates (Thermo Fisher Scientific) in desired densities for experiments. Half of the maturation medium was changed daily until D23--24 when experiments were performed. To ensure the functionality of the cells after longer maturation, iMGLs from *APOE* lines were maturated in presence of IL-34 (100 ng/mL) and MCSF (5 ng/mL) until D42, and similar results were obtained for cytokine secretion, qRT-PCR and phagocytosis.

Statistical Analysis {#sec4.3}
--------------------

Statistical analysis was performed using Graphpad Prism 7. Comparisons involving two groups were analyzed with two-tailed Student's t test. One-way ANOVA was utilized for comparisons with more than two groups followed by Tukey\'s post hoc test. Two-way ANOVA was utilized for comparisons of genotypes and treatment groups and followed by Bonferroni\'s multiple-comparison post hoc test. Corrected p values for multiple comparisons were reported. Differences were considered significant when p \< 0.05.
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